Staff Investigators

$45,782P30FY2007CANIH

Wake Forest University Health Sciences, Winston-Salem NC

Investigators

Linked publications & trials

Paper 39677829 Paper 39671912 Paper 39568014 Paper 39531120 Paper 39470689 Paper 39469826 Paper 39404291 Paper 39363952 Paper 39359617 Paper 39266299 Paper 39230469 Paper 39172521 Paper 39082645 Paper 38956976 Paper 38916900 Paper 38892202 Paper 38845812 Paper 38798474 Paper 38776486 Paper 38701438 Paper 38687384 Paper 38664967 Paper 38637361 Paper 38611037 Paper 38504345 Paper 38473386 Paper 38459766 Paper 38405813 Paper 38387528 Paper 38372596 Paper 38345536 Paper 38317577 Paper 38305778 Paper 38274305 Paper 38249330 Paper 38191961 Paper 38186361 Paper 38178811 Paper 38133583 Paper 38127055 Paper 38051771 Paper 38035561 Paper 38030790 Paper 38006690 Paper 37998334 Paper 37980711 Paper 37891454 Paper 37856922 Paper 37813818 Paper 37798249 Paper 37699885 Paper 37647863 Paper 37605420 Paper 37586363 Paper 37577665 Paper 37479733 Paper 37462260 Paper 37375569 Paper 37368157 Paper 37367944 Paper 37352974 Paper 37285464 Paper 37246644 Paper 37246617 Paper 37228440 Paper 37224410 Paper 37199326 Paper 37126558 Paper 37119835 Paper 37096778 Paper 37058685 Paper 36990930 Paper 36970170 Paper 36960673 Paper 36859704 Paper 36856803 Paper 36853655 Paper 36823339 Paper 36795229 Paper 36791643 Paper 36773459 Paper 36759296 Paper 36754945 Paper 36753275 Paper 36752903 Paper 36719889 Paper 36689691 Paper 36626203 Paper 36593067 Paper 36545790 Paper 36537790 Paper 36525371 Paper 36418073 Paper 36394559 Paper 36373761 Paper 36355119 Paper 36305012 Paper 36291886 Paper 36285743 Paper 36239407

Abstract

Two staff investigators are proposed, both to serve in the function as Deputy Associate Directors for Clinical Research. Dr. Afshin Dowlati, an expert in novel therapeutic development in lung cancer, and Dr. John Sweetenham, an expert in lymphoma therapeutics, are both accomplished clinical investigators with considerable leadership capacity to coordinate clinical trials research emphasizing investigator-initiated efforts. As staff investigators, they will have focused time to devote to clinical trials development and oversight with special emphasis on investigator-initiated trials that cut across scientific programs and involve the Case CCC clinical trials disease teams. As staff investigators, they will have the prominence and authority to assist investigators in protocol development and design, and in efficient, safe management with a high degree of quality assurance during early phase drug development.

View original record on NIH RePORTER →